Universal American Corp. v. Partners Healthcare Solutions Holdings, L.P.

61 F. Supp. 3d 391, 2014 WL 3703867, 2014 U.S. Dist. LEXIS 100654
CourtDistrict Court, D. Delaware
DecidedJuly 24, 2014
DocketCivil Action No. 13-1741-RGA
StatusPublished
Cited by15 cases

This text of 61 F. Supp. 3d 391 (Universal American Corp. v. Partners Healthcare Solutions Holdings, L.P.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Universal American Corp. v. Partners Healthcare Solutions Holdings, L.P., 61 F. Supp. 3d 391, 2014 WL 3703867, 2014 U.S. Dist. LEXIS 100654 (D. Del. 2014).

Opinion

MEMORANDUM OPINION

ANDREWS, U.S. DISTRICT JUDGE:

Before the Court is Defendants’ Motion to Dismiss Plaintiffs Complaint (D.I.17) filed on December 23, 2013. The motion is fully briefed (D.I. 18, 21 & 26) and oral argument was held on May 23, 2014. For the reasons that follow, the Court will grant the Defendants’ motion to dismiss Counts I-YI and VIII, with leave to amend.

I. BACKGROUND

This dispute arises out of a merger between plaintiff Universal American Corporation (“Universal”) and Partners Healthcare Solutions, Inc. (“APS”). Universal provides insurance and health benefits mainly to enrollees in the federal Medicare program. (D.I.l, ¶ 22). APS offers specialty health care solutions that enable its customers, primarily state Medicaid agencies, to improve the quality of care and decrease costs. These services include case management and care coordination, clinical quality and utilization review, and behavioral health services. (Id., ¶¶ 23-24).

APS’s post-merger performance fell substantially short of both parties’ expectations. Universal claims this was due to an organized fraud scheme, and Universal filed suit against the individuals and entities that it claims were in charge of APS. Prior to the merger, APS was a portfolio company of GTCR, a private equity firm. David Katz is a Managing Director of GTCR, which is the general partner of GTCR Co-Invest and GTCR Partners IX. GTCR Partners IX, in turn, is the general partner of GTCR Fund IX/A and GTCR Fund IX/B.1 GTCR Co-Invest, GTCR Fund IX/A, and GTCR Fund IX/B are all [395]*395limited partners of APSLP,2 a Delaware limited partnership that was formed to hold APS. The leadership of APS was organized as follows: Gregory Scott served as the CEO, Jerome Vaccaro was the President and COO, and John McDon-ough acted as the CFO. (Id., ¶¶ 13-15). McDonough, Scott, and Vaccaro3 are all named defendants in this case, and served as limited partners of APSLP. Defendants Katz and Scott also sat on APS’s five-member board.

Universal asserts nine counts ranging from securities fraud and common law fraud to aiding and abetting and unjust enrichment. The Defendants have moved to dismiss the Complaint in its entirety for failure to state a claim upon which relief can be granted. (D.I.17). Each count will be addressed in order.

II. LEGAL STANDARD

When reviewing a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), the Court must accept the Complaint’s factual allegations as true. See Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555-56, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). Rule 8(a) requires “a short and plain statement of the claim showing that the pleader is entitled to relief.” Id. at 555, 127 S.Ct. 1955. The factual allegations do not have to be detailed, but they must provide more than labels, conclusions, or a “formulaic recitation” of the claim elements. Id. (“Factual allegations must be enough to raise a right to relief above the speculative level ... on the assumption that all the allegations in the complaint are true (even if doubtful in fact).”). Moreover, there must be sufficient factual matter to state a facially plausible claim to relief. Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009). The facial plausibility standard is satisfied when the complaint’s factual content “allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. (“Where a complaint pleads facts that are merely consistent with a defendant’s liability, it stops short of the line between possibility and plausibility of entitlement to relief.” (internal quotation marks omitted)).

III. DISCUSSION

A. Securities Fraud Under Section 10(b) of the Exchange Act (Count I)

Universal alleges that APSLP and the Individual Defendants committed securities fraud under Section 10(b) of the Securities Exchange Act of 1934 (“the Exchange Act”).. In order to state a claim under Section 10(b) of the Exchange Act and SEC Rule 10b-5, the plaintiff must prove: “(1) a material misrepresentation or omission by the defendant; (2) scienter; (3) a connection between the misrepresentation or omission and the purchase or sale of a security; (4) reliance upon the misrepresentation or omission; (5) economic loss; and (6) loss causation.” Amgen Inc. v. Conn. Ret. Plans & Trust Funds, - U.S. -, 133 S.Ct. 1184, 1191-92, 185 L.Ed.2d 308 (2013) (quoting Matrixx Initiatives, Inc. v. Siracusano, — U.S. -, 131 S.Ct. 1309, 1317, 179 L.Ed.2d 398 (2011)). Pursuant to Federal Rule of Civil Procedure 9(b), the above elements must be pled “with particularity,” and, under the Private Securities Litigation Reform Act (“PSLRA”), the pled facts must give “rise to a strong inference that the defendants] acted with the required state of mind.” 15 U.S.C. § 78u-4(b)(2); Institutional Inves[396]*396tors Grp. v. Avaya, Inc., 564 F.3d 242, 253-54 (3d Cir.2009); see also In re Rockefeller Ctr. Props., Inc. Sec. Litig., 311 F.3d 198, 217 (3d Cir.2002) (“Rule 9(b) requires, at a minimum, that plaintiffs support their allegations of securities fraud with all of the essential factual background that would accompany ‘the first paragraph of any newspaper story’ — that is, the ‘who, what, when, where and how’ of the events at issue.”). For the reasons explained below, Count I is dismissed with leave to amend.

In contesting the sufficiency of Universal’s federal securities claim, the Defendants raise two main arguments: that reliance cannot be proven because of the anti-reliance provision in the Merger Agreement, and that the scienter of the Individual Defendants is not adequately pled. Federal securities fraud claims cannot be dismissed based solely on the presence of a contractual anti-reliance provision. Section 29(a) of the Exchange Act provides: “Any condition, stipulation, or provision binding any person to waive compliance with any' provision of this chapter or of any rule or regulation thereunder, or of any rule of a self-regulatory organization, shall be void.” 15 'U.S.C. § 78cc(a). The Third Circuit has held Section 29(a) “forecloses anticipatory waivers of compliance with the duties imposed by Rule 10b-5.” AES Corp. v. Dow Chem. Co., 325 F.3d 174, 180 (3d Cir.2003) (“We believe the conclusion inescapable that enforcement of the non-reliance clauses to bar [the buyer’s] fraud claims as a matter of law would be inconsistent with Section 29(a).”). Therefore, the Court rejects Defendants’ contention that the anti-reliance provision in the merger agreement (D.I.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
61 F. Supp. 3d 391, 2014 WL 3703867, 2014 U.S. Dist. LEXIS 100654, Counsel Stack Legal Research, https://law.counselstack.com/opinion/universal-american-corp-v-partners-healthcare-solutions-holdings-lp-ded-2014.